FDA has approved Merck and Pfizer’s oral SGLT-2 inhibitor, Steglatro (ertugliflozin) tablets, and Steglujan (ertugliflozin + sitagliptin) as an adjunct to diet and exercise for improving glycemic control in patients with type 2 diabetes. The FDA also approved Segluromet (ertugliflozin + metformin) for the same indication in patients already treated with Steglatro or metformin with inadequately controlled type 2 diabetes and patients who are already treated with combination of ertugliflozin and metformin.